Technical Analysis for ABUS - Arbutus Biopharma Corporation
|Grade||Last Price||% Change||$ Change|
ABUS closed up 1.92 percent on Thursday, February 23, 2017, on 9 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Mar 7
Trend Table & Recent Alerts
|Weak or Absent||Down||Flat||Flat|
|See historical ABUS trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 23||Crossed Above 50 DMA||Bullish||0.00%|
|Feb 23||Narrow Range Bar||Range Contraction||0.00%|
|Feb 23||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.00%|
|Feb 23||180 Bullish Setup||Bullish Swing Setup||0.00%|
|Feb 22||Fell Below 50 DMA||Bearish||1.92%|
|Feb 21||Narrow Range Bar||Range Contraction||-1.85%|
|Feb 16||50 DMA Support||Bullish||-1.85%|
|Feb 16||Shooting Star Candlestick||Bearish||-1.85%|
|Feb 16||Doji - Bearish?||Reversal||-1.85%|
|Feb 16||Lizard Bearish||Bearish Day Trade Setup||-1.85%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The companys products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Is ABUS a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ABUS news...
|52 Week High||5.48|
|52 Week Low||2.35|
|200-Day Moving Average||3.35|
|50-Day Moving Average||2.64|
|20-Day Moving Average||2.61|
|10-Day Moving Average||2.65|
|Average True Range||0.12|
|Chandelier Exit (Long, 3 ATRs)||2.49|
|Chandelier Exit (Short, 3 ATRs)||2.71|
|Upper Bollinger Band||2.74|
|Lower Bollinger Band||2.48|
|Percent B (%b)||0.65|